The great debate: are CTCs ready for prime time?

被引：1

作者：

Samson, Susan ^{[1
]}

Baas, Carole ^{[2
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Breast Oncol Program, Breast Sci Advocacy Core, San Francisco, CA 94143 USA

[2] NCI, Off Advocacy Relat, Bethesda, MD 20892 USA

来源：

CONVERGENT SCIENCE PHYSICAL ONCOLOGY | 2015年 / 1卷 / 01期

关键词：

cancer; circulating tumor cells; prostate cancer; bevacizumab; convergent science; patient advocacy;

D O I：

10.1088/2057-1739/1/1/017001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 5 条

[1] The Contribution of Angiogenesis to the Process of Metastasis [J].

Bielenberg, Diane R. ;

Zetter, Bruce R. .

CANCER JOURNAL, 2015, 21 (04) :267-273

[2]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[3] Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? [J].

Montero, Alberto J. ;

Escobar, Mauricio ;

Lopes, Gilberto ;

Glueck, Stefan ;

Vogel, Charles .

CURRENT ONCOLOGY REPORTS, 2012, 14 (01) :1-11

[4]

Stevenson CE, 2012, FUTURE ONCOL, V8, P403, DOI [10.2217/FON.12.22, 10.2217/fon.12.22]

[5] Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma [J].

Turley, Ryan S. ;

Fontanella, Andrew N. ;

Padussis, James C. ;

Toshimitsu, Hiroaki ;

Tokuhisa, Yoshihiro ;

Cho, Eugenia H. ;

Hanna, Gabi ;

Beasley, Georgia M. ;

Augustine, Christina K. ;

Dewhirst, Mark W. ;

Tyler, Douglas S. .

CLINICAL CANCER RESEARCH, 2012, 18 (12) :3328-3339

← 1 →